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PURPOSE: Liver metastases from renal cell carcinoma (RCC) are not uncommon in the course of disease. However,
data about tumor response to intraarterial therapy (IAT) are scarce. This study assessed whether changes of enhancing
tumor volume using quantitative European Association for the Study of the Liver (qEASL) on magnetic resonance
imaging (MRI) and computed tomography (CT) can evaluate tumor response and predict overall survival (OS) early after
therapy. METHODS AND MATERIALS: Fourteen patients with liver metastatic RCC treated with IAT (transarterial
chemoembolization: n= 9 and yttrium-90: n= 5) were retrospectively included. All patients underwent contrast-
enhanced imaging (MRI: n= 10 and CT: n= 4) 3 to 4 weeks pre- and posttreatment. Response to treatment was
evaluated on the arterial phase using Response EvaluationCriteria in Solid Tumors (RECIST),World HealthOrganization,
modifiedRECIST, EASL, tumor volume, andqEASL. Paired t testwasused to comparemeasurementspre- andpost-IAT.
Patients were stratified into responders (≥65%decrease in qEASL) and nonresponders (b65%decrease in qEASL). OS
was evaluated using Kaplan-Meier curves with log-rank test and the Cox proportional hazard model. RESULTS: Mean
qEASL (cm3) decreased from 93.5 to 67.2 cm3 (P= .004) and mean qEASL (%) from 63.1% to 35.6% (P= .001). No
significant changes were observed using other response criteria. qEASL was the only significant predictor of OS when
used to stratify patients into responders and nonresponders with median OS of 31.9 versus 11.1 months (hazard ratio
[HR], 0.43; 95% confidence interval [CI], 0.19-0.97; P= .042) for qEASL (cm3) and 29.9 versus 10.2 months (HR, 0.09;
95% CI, 0.01-0.74; P= .025) for qEASL (%). CONCLUSION: Three-dimensional (3D) quantitative tumor analysis is a
reliable predictor ofOSwhen assessing treatment response after IAT in patientswithRCCmetastatic to the liver. qEASL
outperforms conventional non-3D methods and can be used as a surrogate marker for OS early after therapy.Translational Oncology (2016) 9, 377–383© 2016 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Renal cell carcinoma (RCC) is the most common primary malignancy
of the kidney and accounts for 2% to 4% of all new cancer cases in
developed countries per year [1,2]. Five-year survival rates for local
tumor stage are high; however, metastases are not uncommon in the
course of disease [3]. In fact, 20% of patients show metastatic spread at
the initial diagnosis, and of all patients who have undergone curative
nephrectomy, 20% to 40% will develop RCC metastases [4,5]. The
liver is one of themost commonmetastatic sites causing a dramatic drop
of the 5-year survival rate to 20% [4,6]. The poor prognosis of the
disease, once it shows metastatic spread, is due to the ineffectiveness of
conventional therapies such as systemic chemotherapy, radiation, or
hormone therapy [7–9]. Improved understanding of the underlying
biology of renal cell cancer has led to new treatment approaches
including targeted therapies such as antiangiogenic agents or tyrosine
kinase inhibitors [7,8]. Beyond that, some selected patients may benefit
from metastasectomy, yet a majority of patients are not amendable for
surgery [10,11]. For those patients, image-guided intraarterial therapies
(IATs) such as transarterial chemoembolization (TACE) as well as
yttrium-90 (Y-90) radioembolization have been used and evaluated in
the past [12,13].
The role of radiological assessment of solid tumors especially for tumor
treatment response cannot be overestimated, and the evaluation of tumor
response to therapy is crucial to the course of treatment [14]. For this
purpose, over the last decades, several radiological response criteria were
established. The World Health Organization (WHO) introduced an
evaluation system for solid liver tumors that is based on the sum of the
product of two-dimensional (2D) diameters of tumor lesions [15]. The
Response Evaluation Criteria in Solid Tumors (RECIST) was
introduced in 2000 (revised in 2009) to address some of the limitations
of the WHO criteria. RECIST measurements are based on the sum of
the one-dimensional (1D) longest diameters [15,16]. However, in terms
of IATs, both criteria are greatly limited because most IATs cause tumor
necrosis without immediate changes on overall lesion size rather than a
decrease of viable tumor tissue [17]. The European Association for the
Study of the Liver (EASL) therefore recommended measuring tumor
response by changes of the uptake of contrast medium by the tumor
tissue [18]. The American Association for the Study of Liver Disease
shared the same approach by suggesting measuring changes in tumor
enhancement as a biomarker of tumor viability and introduced the
modified RECIST (mRECIST) criteria [19]. Yet, all 1D and 2D
evaluation methods are flawed with a limited reproducibility and an
essential inaccuracy when assessing the entity of necrotic and heterogenic
tumor lesions [20,21]. These clinically relevant limitations have led to
the development of three-dimensional (3D) quantitative image analysis
techniques that are able to achieve a reproducible, biologically accurate,
and clinically practicable tumor evaluation [17,22,23]. The purpose of
this study is to assess whether changes of enhancing tumor volume using
quantitative EASL (qEASL) on magnetic resonance imaging (MRI) and
computed tomography (CT) can evaluate tumor response and predict
survival after one session of IAT.
Methods and Materials
Study Design and Cohort
The study was compliant with the Health Insurance Portability
and Accountability Act and approved by the Institutional Review
Board. This two-center study consisted of patients with liver
metastases from RCC treated with TACE or Y-90 procedures at
the Johns Hopkins Hospital, Baltimore and the Northwesternprospectively collected imaging databases at both institutions
identified 24 patients [23].
Patients that were included into the final survival analysis fulfilled the
following criteria: 1) diagnosis of RCC liver metastases confirmed by
pathological criteria; 2) patientswere IATnaive; and 3) patients underwent
dynamic contrast-enhanced MR or CT imaging before and after the first
IAT. Seven patients were excluded for the following reasons: previous
IAT (n= 3) and absence of baseline and/or follow-upMRI (n= 7). On the
basis of these criteria, the final study population included 14 patients.
IAT Protocol
TACE. All TACE procedures were performed by the same
interventional radiologist (Jean-Francois Geschwind) with 18 years of
experience in hepatic interventions by using a consistent approach as
reported previously [24]. Briefly, angiographic steps were performed
with contrast runs from the celiac trunk and the superior mesenteric
artery to define the hepatic arterial anatomy, to determine portal venous
patency, and to evaluate tumor vascularity. The contrast agent used was
Oxilan (Guerbet, France). Patients were treated with selective (lobar or
segmental) and super-selective injections. A solution containing 50 mg
of doxorubicin and 10 mg of mitomycin-C in a 1:1 mixture with
Lipiodol (Guerbet, France) was infused and followed by administration
of 100- to 300-μm–diameter microspheres (Embospheres; Merit
Medical, South Jordan, UT). Substantial arterial flow reduction to the
tumor was defined as the technical end point of embolization.
Y-90. All Y-90 procedures were performed by one interventional
radiologist (Riad Salem) with over 15 years of experience in hepatic
interventions. Patients were treated based on previously published
recommendations and guidelines using a selective segmental or lobar
treatment with glass microspheres loaded with Y-90 (TheraSphere;
Nordion,Ottawa,Canada) [25,26]. Prior to treatment, an angiogramwas
performed in order to embolize parasitizing arteries and optimize catheter
tip positioning. Furthermore, 99technetium-macroaggregated albumin
was infused to estimate pulmonary and gastrointestinal shunting.
MR and CT Imaging Protocol
All patients underwent dynamic contrast-enhanced MR or CT
imaging at baseline and approximately 3 to 4 weeks after IAT. MRIs
were obtained on a 1.5-T MRI scanner (Magnetom Avanto; Siemens
Medical Solutions, Forchheim, Germany) using a phased array torso
coil. Standard MR liver protocol included the following: axial
T2-weighted fast spin-echo images, axial single-shot breath-hold
gradient-echo diffusion-weighted echo-planar images, and axial
breath-hold unenhanced and contrast-enhanced (0.1 mmol/kg of
intravenous gadodiamide [Omniscan; Amersham, Princeton, NJ])
T1-weighted 3D fat-suppressed spoiled gradient-echo. CT scans were
obtained on a Lightspeed scanner (GE Healthcare, Princeton, NJ). A
triphasic contrast-enhanced CT liver protocol was employed that used a
standard power injector (Medrad, Indianola, PA) connected to an
intravenous catheter to inject 125 ml of Omnipaque 350 (GE
Healthcare) at a rate of 4 to 5 ml/sec. All contrast-enhanced images
were acquired in the arterial, portal venous, and delayed phases (20, 70,
and 180 seconds after intravenous contrast administration, respectively).
Image Data Analysis
Conventional Response Criteria. Two independent radiological
readers (one board-certified radiologist (Rüdiger Egbert Schernthaner)
with 8 years of experience in abdominal imaging and a radiological reader
(Florian Nima Fleckenstein) with 1 year of experience) conducted
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ensure careful comparison of pre- and posttreatment findings. Readers
were blinded to patient survival and clinical data. Any discrepancy was
resolved by consensus. All measurements were done using standardized
electronic calipers by using Digital Imaging in Communications and
Medicine files.
Volumetric Response Criteria. Semiautomatic quantitative 3D-image
analysis was done by a radiological reader (Florian Nima Fleckenstein) in
training with 1 year of experience in the field of volumetric image analysis
closely supervised by a board-certified radiologist (Rüdiger Egbert Schernthaner)
with 8 years of experience in abdominal MRI.
Quantitative volumetric tumor analysis of the target lesions was done
using a semiautomatic 3D segmentation software (Medisys; Philips
Research, Suresnes, France) as previously described [22]. Briefly, a
segmentation mask was semiautomatically created for every tumor lesion
on the arterial phase of the contrast-enhanced baseline and follow-upMR
and CT images (Figure 1,A and B). The arterial phase was chosen due to
the hypervascular character of RCC metastases. Overall tumor volume
defined as volumetric RECIST (vRECIST) was expressed in cubic
centimeters (cm3) directly calculated from the generated segmentation
masks. Figure 1,C andD illustrates the corresponding 3Dmodels. These
3D masks were then used for quantitative analysis of the tumor
enhancement (qEASL). In order to remove any background signal, the
precontrast scan (Figure 1, E and F) was subtracted from the
arterial-phase scan (Figure 1, A and B), resulting in images that only
show effective contrast uptake during the arterial phase. In the next step, a
region of interest (ROI) formed by 1 cm3 was placed in an area of
extratumoral liver parenchyma as a reference in order to calculate the relative
contrast enhancement (Figure 1,G andH). Quantitative volumetric tumor
enhancementwas expressed in cubic centimeter for each lesion qEASL (cm3)
and percentage of enhancing tumor volume qEASL (%). The software
automatically generated a color map in order to visualize the enhancement
pattern (blue representing nonenhancing necrotic tissue and red representing
viable, enhancing tumor tissue; Figure 1, G and H). The accuracy,
reader-independent reproducibility of semiautomatic tumor segmentation, as
well as the radiological-pathological validation of 3D quantitative tumor
enhancement analysis have been reported previously [17,21,27].
Tumor Response Assessment
Tumor response to IAT procedures was evaluated according to the
WHO, RECIST, EASL, mRECIST, vRECIST, and qEASL criteria,
respectively. Due to the fact that no guidelines for volumetric tumor
response criteria exist and for the purpose of a unified and simplified
response assessment in a clinical setting, we selected cutoff values that are
based on the currently used RECIST and mRECIST criteria for
vRECIST and qEASL thresholds. A decrease of 30% was defined as
partial response (PR) using the 1D evaluation criteria RECIST and
mRECIST. According to the formula volume = 4/3πr3, this corresponds
to a decrease of 65% of tumor volume. Complete response (CR) was
defined as the disappearance of the target lesion. Both CR and PR were
considered objective tumor response. Patients with objective response were
classified as responders. Patients with stable disease (SD, no change in tumor
size) and progressive disease (PD, tumor growth) were classified as
nonresponders. The accuracy and value of these thresholds were described in
previous works [22,28]. Table 1 provides an overview of the different cutoffs.
Statistical Analysis and Survival Assessment
Descriptive statistics were used to summarize the data.Mean and range
were used for continuous variables; and frequency and percent, for
nominal data. Reader agreement of non-3D measurements was assessedusing intraclass correlation coefficient. Significance levels and confidence
intervals (CIs) were calculated. Student's t test was used to compare
tumor size, volume, and enhancement prior and after IAT in order to
evaluate tumor response to treatment. P values ≤ .05 were defined as
statistically significant. Overall survival (OS) was defined as the time from
the date of treatment to the date of death. Patients lost in follow-up or
alive at the end-of-observation date (November 5, 2014) were censored.
Kaplan-Meier survival curves were plotted for each method using the
described thresholds. Median OS and the 95% CI were calculated. The
predictive value of each method was assessed by Cox proportional hazard
modeling (HR). All statistical analyses were performed using the statistical
software R (R Foundation for Statistical Computing, Version 3.1.2,
Vienna, Austria, 2014) and SPSS (IBM, Version 22, Armonk, NY).
Results
Patient Characteristics, Treatment, and Interreader Agreement
Table 2 summarizes baseline data of the patient cohort. Mean lesion
sizewas 7.20 ± 2.75 cm.Mean follow-up periodwas 24.8 ± 28.4months
(range, 2.1-114.7). Mean time from RCC diagnosis to liver metastasis
was 53.9 ± 62.1 months (range, 0-203.2). Mean time from baseline
MRI to IATwas 2.0 ± 1.7 weeks (range, 0-6) and from IAT to follow-up
MRI 3.9 ± 1.4 weeks (range, 3-8). A mean of 2.1 ± 1.2 (range, 1-4) IAT
procedures was performed per patient for a total of 29 treatments. For
the first round of IAT treatments, a total number of 5 (36%) Y-90 and
9 (64%) TACE procedures were performed. The targeted liver lobe was
in 8 (64%) cases the right and in 5 (36%) cases the left liver lobe. All IAT
procedures were technically successful, and no relevant complications or
toxicities were noted. Furthermore, there were no significant changes in
pre- and posttreatment Eastern Cooperative Oncology Group (ECOG)
performance score. After the first treatment, 6 (43%) patients were
assigned an ECOG performance score of 0, and 8 (57%) patients were
assigned an ECOG performance score of 1. Of note, interreader
agreement was excellent with intraclass correlation coefficients for
RECIST, WHO, mRECIST, and EASL measurements of 0.968,
0.945, 0.966, and 0.959.
Image Analysis
Table 3 summarizes pre- and posttreatment values as measured by
conventional response criteria such as RECIST, WHO, mRECIST,
and EASL as well as by volumetric assessment methods such as
vRECIST, qEASL (%), and qEASL (cm3). None of the conventional
response criteria or vRECIST could show significant changes after
IAT. There was a significant (P= .004) decrease of enhancing tumor
volume (qEASL [cm3]) after IAT as well as a significant decrease of
percentage of enhancing tumor (qEASL [%]) (P= .001) after IAT.
Tumor Response Assessment
Conventional Response Criteria. According to the RECIST criteria,
12 (86%) patients showed SD and 2 (14%) PD. The WHO criteria
classified 9 (64%) as SD and 5 (36%) patients as PD. Stratification
following the mRECIST criteria classified 1 (7%) patient as CR, 4
(29%) patients as PR, 8 (57%) patients as SD, and 1 (7%) patient as
PD. When using EASL guideline criteria, 1 (7%) patient showed CR,
3 (21%) patients PR, 7 (50%) patients SD, and 3 (21%) patients PD.
Volumetric Response Criteria. According to vRECIST, 13 (93%)
patients showed SD and 1 (7%) patient PD. When using qEASL (cm3),
4 (29%) patients were classified as PR and 10 (71%) patients as SD.
According to the qEASL (%) criteria, 6 (43%) patients showed PR and
8 (57%) patients showed SD.
Figure 1. Quantitative volumetric contrast-enhanced MRI assessment technique (qEASL). The left column represents baseline MRI, and
the right column represents the follow-up MRI after IAT. (A and B) Semiautomated tumor segmentation on the arterial phase of a
contrast-enhanced MRI. (C and D) The corresponding volume of the segmented tumor in a 3D model. (E and F) The precontrast MR
sequence to demonstrate baseline background signal intensity of the tumors. (G and H) The qEASL color maps of the tumor on the
subtracted MRI scan (the scan before contrast material [E and F] was subtracted from the arterial phase scan [A and B] to remove any
background signal intensity). Color maps: Red represents maximum enhancement, and blue represents no enhancement, normalized by
the ROI. Green box: 3D ROI used as the reference background of image intensity.
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By the end-of-observation date, a total of 11 patients (79%) were
deceased. The median OS of the study cohort was 11.6 months (95%CI, 5.9-39.5). According to the anatomic criteria RECIST, WHO, and
vRECIST, all patients were classified as nonresponder. Hence,
stratification was not possible and no survival analysis was conducted.
Table 1. Response Criteria
WHO RECIST EASL mRECIST vRECIST qEASL (cm3) qEASL (%)
CR Disappearance of all target lesions Disappearance of all
target lesions
Disappearance of all enhancing
tissue in all target lesions
Disappearance of all
enhancing tissue in all
target lesions
Disappearance of all
target lesions
Disappearance of all
enhancing tissue in all
target lesions
Disappearance of all
enhancing tissue in all
target lesions
PR ≥50% decrease in the sum of the
product of bidimensional
diameter of the target lesions
≥30% decrease in the
sum of the longest
diameter of the target
lesions
≥50% decrease in the sum of the
product of bidimensional diameter
of enhancing tissue of the lesions
≥30% decrease in the sum of
the longest enhancing
diameter of the target lesions
≥65% decrease in the
sum of the volume of
the target lesions
≥65% decrease in the
sum of enhancing tissue
volume of the lesions
≥65% decrease in the sum
of percentage of
enhancing tissue of the
lesions
PD ≥25% increase in the sum of
the product of bidimensional
diameter of the target lesions
≥20% increase in the
sum of the longest
diameter of the target
lesions
≥25% increase in the sum of the
product of bidimensional diameter
of the lesions
≥20% increase in the sum of
the longest enhancing
diameter of the target lesions
≥73% increase in the
sum of the volume of
the target lesions
≥73% increase in the
sum of enhancing tissue
volume of the lesions
≥73% increase in the sum
of percentage of
enhancing tissue of the
lesions
SD Any case that does not qualify
for CR, PR, or PD
Any case that does not
qualify for CR, PR,
or PD
Any case that does not qualify for
CR, PR, or PD
Any case that does not
qualify for CR, PR, or PD
Any case that does
not qualify for CR,
PR, or PD
Any case that does not
qualify for CR, PR,
or PD
Any case that does not
qualify for CR, PR, or PD
Note: RECIST mRECIST are calculated by measuring the longest diameter of the enhancing tumor in the axial plane. WHO is calculated by measuring the longest diameter of the tumor in the axial plane
and by drawing a line perpendicular to it. EASL is calculated by measuring the longest diameter of the enhancing tumor in the axial plane and by drawing a line perpendicular to it. qEASL (cm3) is
calculated by measuring the volume of enhancing tumor. qEASL (%) is calculated by measuring the percentage of enhancing tumor in the lesion volume.
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to the remaining assessment criteria. qEASLs (cm3 and%) were the only
methods to show a significant stratification of patients into responders
and nonresponders. Median OS for qEASL (cm3) was 11.1 months for
nonresponders versus 31.9 months for responders (HR, 0.43; 95% CI,
0.19-0.97; P= .042). For qEASL (%) assessment, the median OS was
10.2 months for nonresponders and 29.9 months for responders (HR,
0.09; 95% CI, 0.01-0.74; P= .025).Table 2. Baseline Patient Characteristics
Parameter N (%)
Demographics
Number of patients 14 (100)
Age
Mean (SD) 65.6 (9.0)
b65 years 6 (43)
≥65 years 8 (57)
Sex
Female 6 (43)
Male 8 (57)
Ethnicity
Caucasian 11 (79)
Asian 2 (14)
Afro-American 1 (7)
Patient and liver assessment
ECOG status
0 9 (64)
1 5 (36)
Child-Pugh class
A 12 (86)
B 2 (14)
Treatment
Kidney
Nephrectomy 14 (100)
Liver
TACE 22 (75)
Y90 7 (25)
Number of IATs
1 6 (43)
2 4 (29)
3 1 (7)
4 3 (21)
Tumor characteristics
Number of lesions 29
Mean lesions per patient (SD) 2.07 (1.17)
Extrahepatic disease 4 (29)Discussion
The main finding of this study is that quantitative volumetric changes
of tumor enhancement (qEASL) reliably reflects therapy response and
predicts survival in patients with metastatic RCC early after the first
IAT procedure.
Metastatic RCC is one of the most treatment-resistant malignancies,
and the prognosis is highly dependent on tumor progression in the liver
[4,7,29]. Therefore, it is crucial to assess tumor response early after
treatment to guide the course of therapy and prevent loss of time.
This study showed that conventional anatomical response assessment
methods (RECIST andWHO) fail to differentiate between responders
and nonresponders. Although mRECIST and EASL are able to identify
response to treatment in some patients, both fail to reach statistical
significance. qEASL is the only set of criteria that reliably predicts
patient survival and can therefore be seen as the ideal assessmentmethod
to evaluate early tumor response to IAT.
One reason uni- and bidimensional tumor response criteria fail to
predict survival might be the wrong assumption that tumor diameter
(RECIST and WHO) and enhancing tumor diameter (mRECIST
and EASL) are directly correlated with the volume of viable tumor. In
fact, most tumors show asymmetrical growth and heterogeneous
patterns of necrosis after treatment, resulting in misleading findings
when using diameter- and enhancing diameter–based methods [30].
Taking these tumor characteristics into account, the intellectual
approach behind qEASL is a 3D quantitative technique that allows to
accurately assess viable tumor volume. Time efficiency and feasibility
in a clinical setting as well as histopathological correlation could be
shown in recent studies [17,31].able 3. TumorChanges in Target Lesions after IATAccording toConventional andVolumetric Criteria
Mean Baseline Value (SD) Mean Follow-Up Value (SD) P Value
onventional response criteria
RECIST (cm) 7.20 (2.75) 7.74 (3.16) .067
WHO (cm2) 419.36 (250.39) 478.06 (291.72) .134
mRECIST (cm) 5.51 (1.81) 5.07 (2.68) .389
EASL (cm2) 240.24 (158.19) 209.46 (178.07) .421
olumetric response criteria
vRECIST (cm3) 170.13 (149.12) 178.30 (162.16) .596
qEASL (cm3) 93.45 (94.23) 67.15 (98.21) .004T
C
VqEASL (%) 63.07 (27.23) 35.63 (29.83) .001
Figure 2. Kaplan-Meier analysis based on target lesion response. (A–D) Survival analysis according to tumor response criteria (mRECIST,
EASL, qEASL [cm3], and qEASL [%]). All patients were nonresponders using WHO, RECIST, and vRECIST criteria; hence, calculation of
survival data was not possible.
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and especially on response to IAT is scarce. The largest prospective study
included 22 patients that were treated repeatedly with TACE [12].
Treatment response was evaluated with the RECIST criteria 4 weeks
after treatment. Partial response was achieved in 13.7%. However,
RECIST failed to predict patient survival, which corresponds with our
findings. In contrast, when tumor response is evaluated with qEASL,
our study is able to reliably identify responders and nonresponders after
IAT and predict survival.
Another retrospective study looked at safety and efficacy of Y-90
radioembolization in six patients with metastatic RCC to the liver[13]. Tumor response of these patients was evaluated using the
mRECIST and EASL criteria. The authors only reported the best
response on any of the follow-up images acquired 2 to 3 months after
IAT and every 3 months thereafter. Three patients showed CR and
one patient PR. However, in terms of survival prediction, a major
drawback of this study is the long time frame needed until treatment
success or failure was reliably evaluated. The advantage of qEASL is
not only the reliable prediction of patient survival but also to do so at
an early time point, approximately 3 to 4 weeks after treatment.
There were several limitations to this study. First, the study cohort
is relatively small. However, patients with liver-dominant metastatic
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without endangering the consistency of treatment protocols. Our
study is a two-center study that includes patients that were treated
with TACE and Y-90. Both techniques form a mainstay of
interventional oncology. The fact that qEASL works regardless of
the used treatment technique is clearly a strength of this study.
Second, for all TACE treatments, only patients with pre- and
posttreatment MRI were included. This might have caused a bias.
However, the measurement of enhancement on CT scans after TACE
is limited by the accumulation of iodized oil in the target region. For
patients with Y-90 treatments, this limitation does not apply, and
response to treatment was measured on MRI as well as on CT scans,
respectively. This is another big advantage of qEASL because it can be
used with both MRI as well as CT scans as long as baseline imaging
and follow-up imaging are consistent. Third, the study lacks
histopathological validation of radiological measurements. Yet, it is
quite unrealistic to acquire this validation because patients not
considered amendable for resection are referred to IAT treatment.
In conclusion, the presented results show that quantitative volumetric
tumor enhancement (qEASL) is an early surrogate biomarker of survival
in patients with RCC metastatic to the liver after one session of IAT.
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